EUCTR2008-004013-94-SE进行中（未招募）不适用
A prospective Phase II study to evaluate alterations in molecular biomarkers in HER2-positive metastatic breast cancer together with assessment of trastuzumab use beyond progression after initial exposure to trastuzumab-taxane based treatment - SHERsig
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Written and signed informed consent prior to beginning protocol-specific procedures.
- •2. Female patients age =18 years.
- •3. Evaluable with or without measurable metastatic breast cancer and at least one metastatic lesion which is amenable to multiple core biopsies.
- •4. HER2-positive metastatic lesion, defined as IHC3+ and/or ISH positive (FISH, CISH or SISH), as confirmed by the central laboratory testing.
- •5. All tumor biopsy material can be made available for central laboratory testing.
- •6. ECOG performance status = 2.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Prior or Current Treatments
- •1. Prior chemotherapy for metastatic disease.
- •2. Prior trastuzumab-based therapy for metastatic breast cancer.
- •3. Prior therapy with capecitabine.
- •4. Prior adjuvant/neoadjuvant trastuzumab, or adjuvant bevacizumab or tyrosine kinase inhibitor (TKI) completed <6 months prior to first study treatment.
- •5. Prior doxorubicin >360 mg/m2 or epirubicin 720 mg/m2 or equivalent.
- •6. Prior adjuvant taxane completed <12 months prior to first study treatment.
- •7. Biopsy of metastatic or breast lesion with fine needle aspiration only.
- •8. CNS disease as the only site of metastatic disease.
- •9. Use of immunotherapy or biological anticancer therapy within 21 days prior to study entry.
- •10. Oral or parenteral anticoagulation within 7 days prior to the baseline biopsy and/or coagulation profile outside the normal laboratory range within 48 hrs prior to the baseline biopsy.
- •11. Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study screening.
- •12. Concurrent immunotherapy or anticancer hormonal therapy.
- •13. Inadequate bone marrow function: ANC < 1.5 x 109/L, platelet count < 100 x 109/L or Hb < 9 g/dL.
- •14. Inadequate renal function: serum creatinine > 2.0 mg/dL or 177 µmol/L.
- •15. Inadequate liver function:
- •serum (total) bilirubin > 1.5 ULN,
- •AST and ALT > 3 x ULN (>6 x ULN for patients with liver metastases),
- •AST or ALT > 3 x ULN concurrent with serum alkaline phosphatase levels > 6 x ULN at baseline.
- •Prior or Concomitant Conditions
- •16. Serious concurrent disease which could affect compliance with the protocol or interpretation of results, including, but not limited to:
- •Known bleeding diastheses
- •Co-morbid condition which does not permit cessation of anti-platelet therapy (such as clopidigrel, aspirin) for 7 days before and after serial core biopsies
- •Existing peripheral neuropathy NCI grade > 2 from any cause
- •Active infection requiring antibiotics
- •Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100 mm Hg)
- •Clinically significant cardiovascular disease: Cerebrovascular accident / stroke (= 6 months prior to registration), myocardial infarction (= 6 months prior to registration), unstable angina, New York Heart Association (NYHA) Class 2 or greater congestive heart failure, serious cardiac arrhythmia requiring medication
- •Dyspnoea at rest requiring supportive oxygen therapy or with significant pleural effusions
- •Patients requiring chronic daily treatment with corticosteroids (dose of >10 mg/day methylprednisolone equivalent) (excluding inhaled steroids)
- •17. Cardiac toxicity during previous trastuzumab treatment that necessitated discontinuation of trastuzumab.
- •18. Left ventricular ejection fraction (LVEF) of < 50% by echocardiogram or MUGA.
- •19. Evidence of any other serious intercurrent disease, metabolic or psychological dysfunction, physical examination finding, or clinical laboratory finding, sociological or geographical condition which would contraindicate the use of an investigational drug, or preclude adequate follow-up and compliance with the study protocol.
- •20. History of another malignancy which could affect compliance with the protocol or interpretation of results. Cancer patients treated with curative intent (including for contralateral invasive or in situ breast cancer) are generally eligible if disease-free for at least 5 years, as are patients treated curatively for ca
研究者
相似试验
进行中（未招募）
1 期
A prospective Phase II study to evaluate alterations in molecular biomarkers in HER2-positive metastatic breast cancer together with assessment of trastuzumab use beyond progression after initial exposure to trastuzumab-taxane based treatment - SHERsigEUCTR2008-004013-94-GBF. Hoffmann-La Roche Ltd.50
进行中（未招募）
不适用
Estudio fase II prospectivo para evaluar alteraciones en biomarcadores moleculares y la administración de trastuzumab tras progresión a la exposición inicial de trastuzumab-taxano en pacientes diagnosticadas de cáncer de mama metastásico HER2-positivoA prospective Phase II study to evaluate alterations in molecular biomarkers in HER2-positive metastatic breast cancer together with assessment of trastuzumab use beyond progression after initial exposure to trastuzumab-taxane based treatment - SHERsigTratamiento de pacientes con cáncer de mama metastásico HER2-positivo Treatment of patients with HER2-positive metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerEUCTR2008-004013-94-ESF. Hoffmann-La Roche Ltd.50
招募中
2 期
A phase II trial of adjuvant chemo-radiation followed by chemotherapy for patients with newly diagnosed endometrial carcinoma at high-risk of relapseACTRN12605000561684Peter MacCallum Cancer Centre40
进行中（未招募）
不适用
An Exploratory Phase 2 Study to Assess the Effect of Dapagliflozin on GlomerularFiltration Rate (GFR) in Subjects with Type 2 Diabetes who have Inadequate Glycemicand Blood Pressure (BP) ControlPharmacogenetics Blood Sample Amendment 01 (v1.0, dated 24-Jul-2009)Type 2 DiabetesEUCTR2009-010221-39-NLBristol Myers Squibb International Corporation150
进行中（未招募）
不适用
A clinical study evaluating the efficacy of topical cromoglicate solution compared to placeboin the treatment of mastocytosisMedDRA version: 15.0Level: PTClassification code 10012812Term: Diffuse cutaneous mastocytosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 15.0Level: LLTClassification code 10056452Term: Indolent systemic mastocytosisSystem Organ Class: 10005329 - Blood and lymphatic system disordersmastocytosisEUCTR2011-006275-20-DEEO Pharma A/S